IMCC vs. XCUR, ATHA, GOVX, MIRA, BTAI, CYTH, APRE, BFRG, CARM, and MEIP
Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Exicure (XCUR), Athira Pharma (ATHA), GeoVax Labs (GOVX), MIRA Pharmaceuticals (MIRA), BioXcel Therapeutics (BTAI), Cyclo Therapeutics (CYTH), Aprea Therapeutics (APRE), Bullfrog AI (BFRG), Carisma Therapeutics (CARM), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical products" industry.
IM Cannabis vs.
Exicure (NASDAQ:XCUR) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.
42.8% of Exicure shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 8.4% of Exicure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Exicure and Exicure both had 2 articles in the media. Exicure's average media sentiment score of 0.66 beat IM Cannabis' score of 0.00 indicating that Exicure is being referred to more favorably in the media.
Exicure has a net margin of 0.00% compared to IM Cannabis' net margin of -25.55%. IM Cannabis' return on equity of -129.86% beat Exicure's return on equity.
Exicure has a beta of 3.81, suggesting that its share price is 281% more volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
IM Cannabis has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.
Exicure received 3 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 47.37% of users gave Exicure an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote.
Summary
Exicure beats IM Cannabis on 9 of the 13 factors compared between the two stocks.
Get IM Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IM Cannabis Competitors List
Related Companies and Tools
This page (NASDAQ:IMCC) was last updated on 1/21/2025 by MarketBeat.com Staff
